-
公开(公告)号：EP4382149A2
公开(公告)日：2024-06-12
申请号：EP24169142.7
申请日：2019-05-08
申请人： Akroswiss AG
IPC分类号： A61M5/31
CPC分类号： A61M11/007 , A61M15/0071 , A61M15/08 , A61M2205/2120130101 , G09B23/285 , A61M2207/0020130101 , A61M2005/311420130101 , A61M2209/04520130101 , A61M11/001 , A61M15/0086 , A61M15/009 , A61M2209/0220130101 , G09B23/30
摘要： The present invention relates to a novel nasal spray containing an aqueous solution or a fluid with an anxiolytic or anticonvulsant substance, wherein the nasal spray is characterized in that with the nasal spray, two sprays with each an equivalent, defined volume of the aqueous solution or liquid of the active agent, can be intranasally administered to a patient and wherein the nasal spray allows for an administration, independent of the spatial orientation of the nasal spray in any position of the patient (standing upright, sitting, lying or in any intermediate position). The nasal spray can be used directly without prior activation. Preferably it is apparent from the nasal spray whether a spray or even a second spray has been made with the nasal spray. Preferably, a spray of the nasal spray can be administered one-handed by the patient or a third person. The active agent in the inventive nasal spray is a benzodiazepine or a GABA-receptor agonist, preferably midazolam or a derivative thereof or a salt of these active agents. The nasal spray according to the present invention may be used for sedation, premedication or treatment of patients with claustrophobia, anxiety disorders or panic attacks or for the treatment of convulsions in CNS diseases, particularly in epileptic seizures or other manifestations of seizures (e.g. febrile convulsions). The invention also relates to a method for hermetically sealing an active agent container for use in supplying an nasal spray in accordance with the invention. The invention also relates to a method of detection by localizing the locally precise administration of an active agent in nasal application, as well as a nasal spray, preferably a bi-dose nasal spray, for which, using the cited method of detection, it has been shown both visually (qualitatively) and quantitatively that an orientation-independent, uniform and locally precise administration of the dose of the active agent onto the nasal mucosa of a patient can be achieved. Also provided is a method for airless and air-tight sealing of an active agent container in accordance with the invention.
-
公开(公告)号：EP4378502A2
公开(公告)日：2024-06-05
申请号：EP24169154.2
申请日：2019-05-08
申请人： Akroswiss AG
IPC分类号： A61M5/31
CPC分类号： A61M11/007 , A61M15/0071 , A61M15/08 , A61M2205/2120130101 , G09B23/285 , A61M2207/0020130101 , A61M2005/311420130101 , A61M2209/04520130101 , A61M11/001 , A61M15/0086 , A61M15/009 , A61M2209/0220130101 , G09B23/30
摘要： The present invention relates to a novel nasal spray containing an aqueous solution or a fluid with an anxiolytic or anticonvulsant substance, wherein the nasal spray is characterized in that with the nasal spray, two sprays with each an equivalent, defined volume of the aqueous solution or liquid of the active agent, can be intranasally administered to a patient and wherein the nasal spray allows for an administration, independent of the spatial orientation of the nasal spray in any position of the patient (standing upright, sitting, lying or in any intermediate position). The nasal spray can be used directly without prior activation. Preferably it is apparent from the nasal spray whether a spray or even a second spray has been made with the nasal spray. Preferably, a spray of the nasal spray can be administered one-handed by the patient or a third person. The active agent in the inventive nasal spray is a benzodiazepine or a GABA-receptor agonist, preferably midazolam or a derivative thereof or a salt of these active agents. The nasal spray according to the present invention may be used for sedation, premedication or treatment of patients with claustrophobia, anxiety disorders or panic attacks or for the treatment of convulsions in CNS diseases, particularly in epileptic seizures or other manifestations of seizures (e.g. febrile convulsions). The invention also relates to a method for hermetically sealing an active agent container for use in supplying an nasal spray in accordance with the invention. The invention also relates to a method of detection by localizing the locally precise administration of an active agent in nasal application, as well as a nasal spray, preferably a bi-dose nasal spray, for which, using the cited method of detection, it has been shown both visually (qualitatively) and quantitatively that an orientation-independent, uniform and locally precise administration of the dose of the active agent onto the nasal mucosa of a patient can be achieved. Also provided is a method for airless and air-tight sealing of an active agent container in accordance with the invention.
-
-
公开(公告)号：EP4378502A3
公开(公告)日：2024-08-14
申请号：EP24169154.2
申请日：2019-05-08
申请人： Akroswiss AG
IPC分类号： A61M15/08 , A61M11/00 , A61M15/00 , A61M5/315 , G09B23/28 , B65B3/00 , B65B7/16 , B65B7/28 , B65B31/02 , B65B31/04 , G09B23/30 , A61M5/31
CPC分类号： A61M11/007 , A61M15/0071 , A61M15/08 , A61M2205/2120130101 , G09B23/285 , A61M2207/0020130101 , A61M2005/311420130101 , A61M2209/04520130101 , A61M11/001 , A61M15/0086 , A61M15/009 , A61M2209/0220130101 , G09B23/30
摘要： The present invention relates to a novel nasal spray containing an aqueous solution or a fluid with an anxiolytic or anticonvulsant substance, wherein the nasal spray is characterized in that with the nasal spray, two sprays with each an equivalent, defined volume of the aqueous solution or liquid of the active agent, can be intranasally administered to a patient and wherein the nasal spray allows for an administration, independent of the spatial orientation of the nasal spray in any position of the patient (standing upright, sitting, lying or in any intermediate position). The nasal spray can be used directly without prior activation. Preferably it is apparent from the nasal spray whether a spray or even a second spray has been made with the nasal spray. Preferably, a spray of the nasal spray can be administered one-handed by the patient or a third person. The active agent in the inventive nasal spray is a benzodiazepine or a GABA-receptor agonist, preferably midazolam or a derivative thereof or a salt of these active agents. The nasal spray according to the present invention may be used for sedation, premedication or treatment of patients with claustrophobia, anxiety disorders or panic attacks or for the treatment of convulsions in CNS diseases, particularly in epileptic seizures or other manifestations of seizures (e.g. febrile convulsions). The invention also relates to a method for hermetically sealing an active agent container for use in supplying an nasal spray in accordance with the invention. The invention also relates to a method of detection by localizing the locally precise administration of an active agent in nasal application, as well as a nasal spray, preferably a bi-dose nasal spray, for which, using the cited method of detection, it has been shown both visually (qualitatively) and quantitatively that an orientation-independent, uniform and locally precise administration of the dose of the active agent onto the nasal mucosa of a patient can be achieved. Also provided is a method for airless and air-tight sealing of an active agent container in accordance with the invention.
-
公开(公告)号：EP4382149A3
公开(公告)日：2024-08-07
申请号：EP24169142.7
申请日：2019-05-08
申请人： Akroswiss AG
IPC分类号： A61M15/08 , A61M11/00 , A61M15/00 , A61M5/315 , G09B23/28 , B65B3/00 , B65B7/16 , B65B7/28 , B65B31/02 , B65B31/04 , G09B23/30 , A61M5/31
CPC分类号： A61M11/007 , A61M15/0071 , A61M15/08 , A61M2205/2120130101 , G09B23/285 , A61M2207/0020130101 , A61M2005/311420130101 , A61M2209/04520130101 , A61M11/001 , A61M15/0086 , A61M15/009 , A61M2209/0220130101 , G09B23/30
摘要： The present invention relates to a novel nasal spray containing an aqueous solution or a fluid with an anxiolytic or anticonvulsant substance, wherein the nasal spray is characterized in that with the nasal spray, two sprays with each an equivalent, defined volume of the aqueous solution or liquid of the active agent, can be intranasally administered to a patient and wherein the nasal spray allows for an administration, independent of the spatial orientation of the nasal spray in any position of the patient (standing upright, sitting, lying or in any intermediate position). The nasal spray can be used directly without prior activation. Preferably it is apparent from the nasal spray whether a spray or even a second spray has been made with the nasal spray. Preferably, a spray of the nasal spray can be administered one-handed by the patient or a third person. The active agent in the inventive nasal spray is a benzodiazepine or a GABA-receptor agonist, preferably midazolam or a derivative thereof or a salt of these active agents. The nasal spray according to the present invention may be used for sedation, premedication or treatment of patients with claustrophobia, anxiety disorders or panic attacks or for the treatment of convulsions in CNS diseases, particularly in epileptic seizures or other manifestations of seizures (e.g. febrile convulsions). The invention also relates to a method for hermetically sealing an active agent container for use in supplying an nasal spray in accordance with the invention. The invention also relates to a method of detection by localizing the locally precise administration of an active agent in nasal application, as well as a nasal spray, preferably a bi-dose nasal spray, for which, using the cited method of detection, it has been shown both visually (qualitatively) and quantitatively that an orientation-independent, uniform and locally precise administration of the dose of the active agent onto the nasal mucosa of a patient can be achieved. Also provided is a method for airless and air-tight sealing of an active agent container in accordance with the invention.
-
-
-
-
搜索结果
5 条记录 (耗时 0.008 秒)
